DENTSPLY SIRONA Inc. (NASDAQ:XRAY) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Monday.

According to Zacks, “Over the last year, DENTSPLY SIRONA traded below the broader industry in terms of prices. The company's higher capital expenditure on product development and tough competition are expected to put margins under pressure. Unfavorable foreign exchange rate and integration risks are the major headwinds in the near term. However robust performance by the company’s flagship dental implants, CAD/CAM systems, imaging systems, treatment centers and orthodontic product platforms hold considerable promise over the long haul. Emerging markets like Asia-Pacific & the Middle East offer healthy growth opportunities on a long-term basis, as they remain vastly untapped with low dental products penetration. The company’s agreements with MedTech bigwigs like Henry Schein and Patterson Companies in Canada are likely to drive sales. DENTSPLY SIRONA has recently witnessed a rebound in sales in Asia, particularly Japan, and strong growth in Russia.”

Other equities analysts have also issued reports about the stock. HC Wainwright restated a “buy” rating and set a $68.00 target price (down from $74.00) on shares of DENTSPLY SIRONA in a research report on Monday, August 14th. Stifel Nicolaus restated a “buy” rating on shares of DENTSPLY SIRONA in a research report on Thursday, October 19th. Morgan Stanley raised their target price on shares of DENTSPLY SIRONA from $66.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, August 10th. TheStreet lowered shares of DENTSPLY SIRONA from a “b” rating to a “c+” rating in a research report on Wednesday, August 9th. Finally, BidaskClub lowered shares of DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $65.60.

DENTSPLY SIRONA (NASDAQ XRAY) traded down 0.37% during mid-day trading on Monday, hitting $61.12. 725,799 shares of the stock traded hands. The stock’s market cap is $14.03 billion. The company has a 50 day moving average of $59.07 and a 200-day moving average of $60.96. DENTSPLY SIRONA has a 12-month low of $52.53 and a 12-month high of $65.68.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.65. The business had revenue of $992.70 million for the quarter, compared to analyst estimates of $1 billion. DENTSPLY SIRONA had a negative net margin of 20.57% and a positive return on equity of 7.24%. The company’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same period last year, the firm posted $0.76 earnings per share. Equities research analysts forecast that DENTSPLY SIRONA will post $2.68 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “DENTSPLY SIRONA Inc. (XRAY) Downgraded to Sell at Zacks Investment Research” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/10/30/dentsply-sirona-inc-xray-downgraded-to-sell-at-zacks-investment-research.html.

A number of large investors have recently bought and sold shares of the stock. Commonwealth Bank of Australia boosted its position in shares of DENTSPLY SIRONA by 19.0% during the 2nd quarter. Commonwealth Bank of Australia now owns 1,626 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 260 shares in the last quarter. Acrospire Investment Management LLC purchased a new stake in shares of DENTSPLY SIRONA during the 2nd quarter worth $113,000. Dupont Capital Management Corp purchased a new stake in shares of DENTSPLY SIRONA during the 2nd quarter worth $116,000. Korea Investment CORP boosted its position in shares of DENTSPLY SIRONA by 139.9% during the 2nd quarter. Korea Investment CORP now owns 2,145 shares of the medical instruments supplier’s stock worth $139,000 after purchasing an additional 1,251 shares in the last quarter. Finally, Sphera Funds Management LTD. purchased a new stake in shares of DENTSPLY SIRONA during the 2nd quarter worth $162,000. Hedge funds and other institutional investors own 93.92% of the company’s stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Get a free copy of the Zacks research report on DENTSPLY SIRONA (XRAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.